Dynamic Technology Lab Private Ltd acquired a new stake in shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 12,603 shares of the biopharmaceutical company’s stock, valued at approximately $132,000.
Other large investors have also bought and sold shares of the company. Louisiana State Employees Retirement System raised its position in Sucampo Pharmaceuticals by 1.0% in the second quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 100 shares in the last quarter. First Citizens Bank & Trust Co. bought a new stake in Sucampo Pharmaceuticals during the second quarter worth about $116,000. JPMorgan Chase & Co. bought a new stake in Sucampo Pharmaceuticals during the second quarter worth about $117,000. Karp Capital Management Corp bought a new position in Sucampo Pharmaceuticals in the first quarter valued at approximately $119,000. Finally, Pinnacle Associates Ltd. bought a new position in Sucampo Pharmaceuticals in the second quarter valued at approximately $122,000. 55.54% of the stock is owned by hedge funds and other institutional investors.
Sucampo Pharmaceuticals, Inc. (NASDAQ SCMP) opened at $10.55 on Friday. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.42 and a current ratio of 5.11. The stock has a market cap of $465.52, a PE ratio of 6.85, a price-to-earnings-growth ratio of 2.34 and a beta of 1.38.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.25 by $0.02. The firm had revenue of $61.27 million during the quarter, compared to the consensus estimate of $58.05 million. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The firm’s revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.30 EPS. equities research analysts expect that Sucampo Pharmaceuticals, Inc. will post 1.13 earnings per share for the current year.
In other Sucampo Pharmaceuticals news, insider Jason Patrick Meyenburg bought 4,000 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were acquired at an average cost of $12.13 per share, with a total value of $48,520.00. Following the completion of the transaction, the insider now owns 30,228 shares in the company, valued at $366,665.64. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of Sucampo Pharmaceuticals stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $12.00, for a total value of $12,000,000.00. The disclosure for this sale can be found here. 4.13% of the stock is owned by corporate insiders.
Several equities research analysts have weighed in on the stock. BidaskClub lowered shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 5th. Maxim Group reiterated a “buy” rating and issued a $23.00 target price on shares of Sucampo Pharmaceuticals in a report on Thursday. Mizuho reiterated a “hold” rating and issued a $12.00 target price on shares of Sucampo Pharmaceuticals in a report on Wednesday. Roth Capital set a $30.00 price objective on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, Leerink Swann began coverage on shares of Sucampo Pharmaceuticals in a report on Monday, August 21st. They set an “outperform” rating and a $15.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $16.50.
TRADEMARK VIOLATION NOTICE: This story was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.com-unik.info/2017/11/04/dynamic-technology-lab-private-ltd-acquires-new-stake-in-sucampo-pharmaceuticals-inc-scmp.html.
Sucampo Pharmaceuticals Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Want to see what other hedge funds are holding SCMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).
What are top analysts saying about Sucampo Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sucampo Pharmaceuticals Inc. and related companies.